Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Journey from Target to T Cell Product: A Platform to identify Opportunities and Overcome Challenges, 2019

Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Journey from Target to T Cell Product: A Platform to identify Opportunities and Overcome Challenges, 2019

  • Pages: 120
  • Geography: Global
  • Delivery Timeline: 7-10 Business Days
  • Publication: Jan, 2019
  • SKU: DISR0005
  • Single User License
    20% Off
    $3600
  • Site License
    30% Off
    $6300
  • Global License
    40% Off
    $8100
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

Chimeric Antigen Receptor T cell overview

A type of engineered T-cells is recognised for its specificity towards target antigens. Chimeric antigen receptor T therapy involves the collection of T-cells from the patient’s immune system, i.e., from his blood and infuses these genetically engineered cells back to the patient’s body to target cancer. The use of Co-stimulatory domains and safety switches in the present CAR T cell technology resulted into the development of new two Chimeric antigen receptor generations that have potential to deal with the adverse events of 1st generation Chimeric antigen receptors more effectively and safely. Probably, this new approach can change the scenario of future cancer treatments.

Chimeric antigen receptor T cells are the fusion proteins of a selected single-chain fragment variable from a particular monoclonal antibody and one or more T-cell receptor intracellular signalling domains. A Chimeric antigen receptor combines antigen-binding domains-most commonly, a single-chain variable fragment (scFv) derived from the variable domains of antibodies with the signalling domains of the TCR chain and additional co-stimulatory domains from receptors, such as CD28, OX40, and CD137. 

DelveInsight Report, “Chimeric Antigen Receptor T cell Immunotherapy - Journey from Target to T Cell Product: A Platform to identify Opportunities and Overcome Challenges, 2019”, emphasises on the currently active Chimeric Antigen Receptor T cell products in research and development.

The report provides an in-depth analysis of critical Chimeric Antigen Receptor market trends and governing factors along with market attractiveness as per segments. The report also provides the qualitative impact of various Chimeric antigen receptor T market forecast factors on different Chimeric Antigen Receptor T market segments and geographies. The comprehensive insights provided in this report will help the companies in identifying better opportunities.

Key questions answered

  • What will CAR-T cell Therapy Global Competitive Landscape change?
  • What is CAR-T combination Therapies?
  • What are Collaborations, Partnering deals and Licensing opportunities?
  • Who are Current Prominent Research Areas and Key Players in the CAR T Cell Therapy Market?
  • What are Pipeline product profiles of CAR-T Technologies and Targeted Antigens?
  • Which drugs are in Clinical trials Landscape and ongoing clinical and non-clinical advancements in the field of CAR T- cell therapy?
  • What is the US, EU and Japan regulatory scenario?
  • How Market Drivers and Barriers will change the Chimeric antigen receptor T market share?
  • What are the Strategies to reduce the cost of CAR-T therapy?
  • Summary of Coverage Policies
  • What is Strategic analysis of Reimbursement Policies for CAR-T cell therapy?
  • What is Cost Analysis- Kymriah versus Yescarta?
  • What are the new developments and the latest trends in CAR-T Cell Therapy?
  • What is Global Chimeric antigen receptor T market size Future Prospects?

Key benefits of Chimeric antigen receptor T cell therapy market report 

The report provides in-depth analysis of the Chimeric Antigen Receptor T cell profiles comprising pre-clinical and clinical studies, Collaborations details and Deal values, Technologies and Targeted antigens, Investments and fundings etc. The report provides the Chimeric Antigen Receptor T licensing opportunities, acquisitions, market drivers and barriers followed by cost-analysis and SWOT Analysis. The report also includes the KOL views on Chimeric Antigen Receptor T Therapy. Additionally, the report covers the Chimeric Antigen Receptor T cell comparative analysis of the sales of two approved drugs (Kymriah and Yescarta). The report also elaborates the unmet needs covered by CAR-T cells highlighting the adverse events, which are significant concerns in the Chimeric antigen receptor T market analysis. The strategists can gain detailed insight and devise appropriate strategies to target a specific market.

Chimeric Antigen Receptor T cell therapy report highlights

The report covers the 100+ companies with 270+ Chimeric Antigen Receptor T therapies, which are present in this field comprising 50+ clinical companies with 90+ products aiming more than 80+ different antigens and more than 20+ different technologies.

1.Report Introduction

2.Report Highlights

3.Scope

4.Executive Summary Snapshot

5.Executive Summary

5.1.1.Key Findings

6.Introduction

6.1.Cancer Immunotherapy

6.2.Adoptive T cell transfer (ACT)

6.3.Chimeric Antigen Receptor (CAR) T-cells

6.4.CARS Generations

6.5.CARs Generations: Snapshot

6.6.CAR-T Cell Therapy Design

6.7.Genetic Engineering of T-Cells

6.8.Necessity of 2nd Generation and 3rd generation CAR Signalling

6.9.Co-stimulatory domains

6.9.1.4-1BB (CD137): Just a glance

6.10.Advantages of CAR-T cells

6.11.Adverse Events with CAR T-cell Therapy

6.11.1.Acute Infusion Reactions

6.11.2.On-target Toxicities

6.11.3.Organ-specific toxicities:

6.12.Limitations of Existing Technologies for CAR T-Cells

7.Marketed Products

7.1.Kymriah: Novartis

7.1.1.Product Description

7.1.2.Regulatory Milestones

7.1.3.Research and Development

7.1.4.Product Development Activities

7.2.Yescarta: Kite Pharma (Gilead Sciences)

7.2.1.Product Description

7.2.2.Regulatory Milestones

7.2.3.Research and Development

7.2.4.Product Development Activities

8.CAR-T Cell Therapy-Analysis

8.1.CAR-T Collaboration Deals

8.1.1.CAR-T Cells Therapy Collaborations and Deal Year

8.1.2.CAR-T Investment Analysis

8.1.3.Collaborations & Deal Value Trends

8.1.4.Companies Collaborations for Future Developments

8.2.CAR-T Acquisitions Deals

8.2.1.CAR-T Cells Therapy Acquisitions Trends

8.2.2.CAR-T Cells Therapy Acquisitions Offerings by Big Giants

8.3.Manufacturing Facilities for the Development of CAR-T cells

8.3.1.Novartis

8.3.2.JW Therapeutics

8.3.3.Gilead Sciences Inc.

8.3.4.Mustang Bio

8.3.5.Novartis and CELLforCURE

8.3.6.Johnson & Johnson

8.3.7.Celgene

8.3.8.Atara Biotherapeutics

8.3.9.TGen, City of Hope

8.4.JCAR015: Major Set Back for Juno Therapeutics

8.5.Allogeneic CAR-T therapy: a promising approach in CAR-T Space

8.6.CAR-T Licensing Opportunities

8.7.Pipeline Scenario

8.7.1.Pipeline Products under Development - An Overview

8.7.2.Pipeline Products under Development by Company

8.7.3.CAR T-cells Therapeutic Areas & Companies

8.7.4.CAR-T cells Targeted Antigens

8.8.Target: CD19 Related Drug Products, Phase & Company

8.8.1.Targets other than CD19, Related drug products, Phase & Company

8.9.CAR T-cell Technologies & Companies Involved

8.10.CAR-T Safety Switches & Company Involved

8.11.Companies with Upcoming CAR-T Therapeutics

9.Pipeline Profiles

9.1.Actinium Pharmaceuticals, Inc.

9.1.1.Iomab-ACT Program- Actinium Pharmaceuticals

9.1.2.Product Profile

9.2. AgenTus Therapeutics

9.2.1.Description

9.2.2.Other Development Activities

9.3. Allogene Therapeutics

9.3.1.Description

9.3.2.Other Developmet Activities

9.3.3.Non-clinical Pipeline Portfolio

9.3.4.ALLO-501 - Allogene Therapeutics Inc.

9.3.5.ALLO-715: Allogene Therapeutics

9.3.6.ALLO- 819: Allogene Therapeutics

9.3.7.CD70 (NHL): Allogene Therapeutics

9.3.8.CD70 (RCC): Allogene Therapeutics

9.3.9.DLL3: Allogene Therapeutics

9.4.Anixa Biosciences (formerly ITUS Corporation)

9.4.1.Description

9.4.2.Other Development Activities

9.4.3.Solid Tumor Therapy Program: Anixa Biosciences

9.5.Arbele Limited

9.5.1.Description

9.5.2.Other Development Activities

9.5.3.Non-clinical Pipeline Portfolio

9.5.4.ARB-301: Arbele Limited

9.5.5.Disruptive CAR-T/TCR-T : Arbele Limited

9.5.6.Disruptive CAR-T/TCR-T : Arbele Limited

9.6.Apceth Biopharma

9.6.1.Description

9.6.2.Apceth-301: Apceth Biopharma

9.7.Aurora Biopharma

9.7.1.Description

9.7.2.AU101: Aurora Biopharma

9.7.3.AU105: Aurora Biopharma

9.7.4.Non-clinical Pipeline Portfolio

9.8.Autolus Limited

9.8.1.Description

9.8.2.Other Development Activities

9.8.3.AUTO3: Autolus Limited

9.8.4.AUTO2: Autolus Limited

9.8.5.AUTO1: Autolus Therapeutics Ltd.

9.9.Avacta Life Sciences Limited

9.9.1.Description

9.9.2.Other Development Activities

9.9.3.Non-clinical Pipeline Portfolio

9.10.Beijing Biohealthcare Biotechnology Co., Ltd

9.10.1.Description

9.10.2.Anti-CD20 chimeric antigen receptor T cell therapy: Beijing Biohealthcare Biotechnology Co.,Ltd

9.10.3.Non-clinical Pipeline Portfolio

9.11.Beijing Doing Biomedical Co., Ltd.

9.11.1.Description

9.11.2.Other Development Activities

9.11.3,Anti-CD19-CAR: Beijing Doing Biomedical

9.11.4,Anti-CD19 anti-CD20 Bispecific CAR-T: Beijing Doing Biomedical

9.12.Beijing Immunochina Medical Science & Technology

9.12.1.Description

9.12.2.IM19 CAR-T: Beijing Immunochina Medical Science & Technology

9.13.Beijing Sanwater Biological Technology Co., Ltd.

9.13.1.Description

9.13.2.CART-19: Beijing Sanwater Biological Technology Co., Ltd.

9.14.Biontech

9.14.1.Description

9.14.2.Other Development Activities

9.14.3.FPI2019: Biontech

9.15.Bellicum Pharmaceuticals Inc.

9.15.1.Description

9.15.2.Other Development Activities

9.15.3.BPX-601: Bellicum Pharmaceuticals Inc.

9.15.4.Anti-GD2-CAR engineered T cells: Bellicum Pharmaceuticals Inc.

9.15.5.Non-clinical Pipeline Potfolio

9.15.6.CD19 CAR-T Cell therapy: Bellicum Pharmaceuticals Inc.

9.15.7.CD123 CARs: Bellicum Pharmaceuticals Inc.

10.CAR-T Therapies Sales: Kymriah & Yescarta

11.Upcoming Technologies Better than CARs

11.1.Unum Therapeutics

11.1.1.Antibody-Coupled T-cell Receptor Technology

11.2.Adaptimmune

11.2.1.Engineered T cell Therapy

12.US, EU and Japan Regulatory Scenario

12.1.USA Scenario

12.1.1.US Regulatory Route to Market

12.1.2.Various Types of expedited approvals in US

12.2.Europe Scenario

12.2.1.EU regulatory route to market

12.2.2.Various Types of expedited approvals in EU:

12.3.Japan Scenario:

12.3.1.Expedited approval system under PMDA

13.Strategic Analysis of Reimbursement Policies for CAR-T Cell Therapy

14.Summary of Coverage Policies

14.1.United States of America

14.1.1.Centers for Medicare & Medicaid Services (CMS): Medicare and Medicaid

14.2.United Kingdom

14.2.1.England's NHS to offer Gilead's Yescarta through Cancer Drugs Fund

15.Strategies to reduce the cost of CAR-T

15.1.Cost-reduction strategies:

16.CAR-T Cell Therapy: Market Drivers and Barriers

17.KOL Views on CAR-T

17.1.What is the KOL impression of CAR T-cell therapy based on prior research and new findings presented during the 2019 ASCO Annual Meeting?

17.2.What new research on CAR T-cell therapy presented at ASCO excited KOL the most?

17.3.What major questions about CAR T-cell therapy remain to be addressed?

17.4.What caution would the KOL give to their peers about administering CAR T-cell therapy?

17.5.How is the cost of CAR T-cell therapy compared with other treatment approaches, and how might that influence treatment decision-making?

18.SWOT Analysis

19.Strategies for CAR T Therapy to Overcome Challenges in Treating Cancers

19.1.1.Armed CAR T cell with “OFF switch,” suicide gene-iCasp9

19.1.2.CAR T cell with “OFF switch”

19.1.3.CAR T cells with “ON switch”

19.1.4.CAR T cells with “ON/OFF switch”

19.1.5.Improving and streamlining the manufacturing process:

20.Global CAR-T Cell Therapy: Market Future Prospects

20.1.Expansion of Indications

20.2.Expansion of Targets

20.3.Enhanced Safety

20.4.High specificity

20.5.Enhanced Efficacy

21.Frequently Asked Questions

22.Report Methodology

22.1.Coverage

22.2.Research Design

22.2.1.Secondary Research

22.2.2.Primary Research

22.2.3.Expert Panel Validation

23.DelveInsight Capabilities

24.Disclaimer

25.About DelveInsight

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Table 1: CARs Generations-Associated Target Antigens and Indications

Table 2: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 3: CAR-T Cells Therapy – University Collaborations and Deal Year, 2019

Table 4: CAR-T Cells Therapy Collaboration Deals and Values, 2019

Table 5: Companies CAR-T Investment for future developments, 2019

Table 6: CAR-T Cells Therapy Acquisitions and Deal Year, 2019

Table 7: Companies open for licensing and collaborations, 2019

Table 8: umber of Products under Development, 2019

Table 9: Number of Products under Development by Companies, 2019

Table 10: Number of Products under Development by Indication, 2019

Table 11: CAR-T cell Targeted Antigens, 2019

Table 12: Number of Products under Development by CD19 Target by Stage of Development, 2019

Table 13: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Table 14: Number of Products Targeting CD19 Antigen, 2019

Table 15: Number of Products Targeting Other Antigens, 2019

Table 16:Number of Technology based Products by Company, 2019

Table 17: Net Product Sales in USD Millions by Quarter / Year

Figure 1: CAR-T Collaboration Deals, 2019

Figure 2: Collaborations and Upfront Deal Values (In million, USD), 2019

Figure 3: Number of Products under Development, 2019

Figure 4: Number of Products under Development by Companies, 2019

Figure 5: Number of Products under Development by Indications, 2019

Figure 6: CAR-T cell Targeted Antigens (%), 2019

Figure 7: Number of Products under Development by CD19 Target by Stage of Development, 2019

Figure 8: Number of Products under Development by CD19 Targets, Company & Phases, 2019

Figure 9: Number of Products under Development by Other Targets and Stage of Development, 2019

Figure 10: Number of Products by Technologies, 2019

Figure 11: Number of Technology based Products by Stage & Company, 2019

Figure 12: Net Product Sales in USD Millions by Quarter / Year

Figure 14: Cost Reduction Strategies for CAR-T Therapy

Figure 15: Strategies for CAR T therapy to overcome challenges in treating cancers

Figure 16: Armed CAR T cell with “OFF switch,” suicide gene-iCasp9 to kill itself by apoptosis

Figure 17: CAR T cell with “OFF switch”- co-expression with a truncated protein or a small epitope peptide

Figure 18: CAR T cells with “ON switch”- small molecules

Figure 19:  CAR T cells with “ON/OFF switch”

Key Companies

Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.